ConferenceSeries Ltd  welcomes Students, Pharmaceutical companies / industries, leading universities and research institutions, presenters, and exhibitors from all over the world to Seoul, South Korea . We are delighted to invite you all to attend and register for the “9^th Annual Congress on Drug Design & Drug Formulation ” (Drug Formulation 2017) which is going to be held during October 19-20, 2017 Seoul, South Korea. We invite you to join us at the Drug Formulation 2017, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Drug Formulation 2017 organizing committee look forward to meeting you in Seoul, South Korea.

Why Korea?

Global Pharmaceutical Industry in its operation and innovation activities is now facing serious challenges resulted by mega trends in healthcare paradigm. Korean R&D-based pharmaceutical companies have been involving in pioneering unmet medical needs areas investing over 65% to their annual net profit with the strong support from the Korean government. Modern pharmaceutical industry in Korea has 110 years of history initiating at the end of the 1800s, when a first modern pharmaceutical company began its operation.

• Although with a comparatively small market size, US$ 16 billion in production occupying 1.5% of global market at present, Korean market is expected to grow up unceasingly with rapid annual growth rate of 10% in domestic market surpassing the world average 3-5%. To overcome the small market size in comparison with bigger market in US, EU etc., the Korean pharmaceutical industry has been accelerating their innovation activities in new drug R&D for early entering the overseas market.
• According to the recent analysis data by Korea Health Industry Development Institute (KHIDI), major 46 R&D-Based Korean pharmaceutical companies recently designated to be innovative pharmaceutical companies by the Ministry of Health & Welfare of Korea will increase R&D investment from 1,272,300 KRW million to 3,879,800 KRW million by 2020.
• As for the Korean pharmaceutical industry, during the past 30 years there has been marvellous advancement in new drug research and development; market-launched 33 new drugs approved by the Korean regulatory agency(MFDS), US-FDA approved 2 drugs, world's first monoclonal antibody bio-similar, around 15 IND-approved(by US FDA, EMA) new drug candidates, 200 or so out-licenced(to 30 countries) new drug candidates & technologies, 300 or so finished drugs & APIs already launched in overseas market including US and EU, 1,000 or so leads or druggable candidates existing in Korean pharmas' labs, 124 to be commercialized in the global market by 2014~2016 etc. Considering the success possibility, 31 of new drugs are expected by 2020.

Korean Pharmaceutical Industry owes these successful innovation activities and future vision to not only their own strong passion & resolute R&D investment for growth strategy through innovation in new drug research and development but also systemic R&D ecosystem surrounding the industry; optimized R&D environment closely linked to the industry and strong governmental support.

Accompanied by 150 or so universities and colleges having strong needs for R&D co-works and technology commercialization with the industry with their excellent IP assets in early stage research areas, 6 major public research institutes(Korea Institute of Science & Technology, Korea Research Institute of Bioscience & Biotechnology, Korea Research Institute of Chemical Technology, Korea Basic Science Institute, Institute Pasteur Korea, Korea Institute of Toxicology) having excellent research abilities in basic & applied science and superior research infrastructure and 19 preclinical trial organizations & 163 clinical trial facilities, most of the R&D based Korean pharmaceutical companies have been pioneering the future with new drug R&D.

Drug Formulation in Asia-Pacific:

Drug delivery refers to technologies, formulations/systems (based on drug vehicles/carriers) and approaches (route of administration) used to deliver drugs for various applications/therapeutic use.  Advanced drug delivery technologies refer to the technologies used for controlling the rate of drug release. The report focuses on modified drug delivery technologies such as extended release (controlled and sustained release), controlled release, targeted release, delayed release and pulsatile release.

• The advanced drug delivery market is expected to increase from about $178.8 billion in 2015 to nearly $227.3 billion in 2020, reflecting a five-year compound annual growth rate (CAGR) of 4.9%. North America leads the global advanced drug delivery market, followed by Europe. However, Asia-Pacific should grow the fastest during the forecast period with a five-year CAGR of 6.4%.

Major associations around the globe:

•  Parenteral Drug Association (PDA)
•  Bioanalytical Focus Group and Ligand Binding Assay
•  American Association of Pharmaceutical Scientists (AAPS)
•  Royal Netherlands Chemical Society
•  US Food and Drug Administration (FDA)
•  American Association for Clinical Chemistry (AACC)
•  American Association of Pharmaceutical Scientists (AAPS)
•  Clinical Trials Information from National Institutes for Health (NIH)
•  ORPHANET Parenteral Drug Association
•  BEBAC Consultancy Services for Bioequivalence and Bioavailability
•  European Generic medicines Association
•  Therapeutics Goods Administration (TGA)

Top-Ranked Pharmaceutical Companies & Pharmacy Colleges:

South korea :

• Seoul Pharm Co. Ltd
• DongA Pharm
• Takeda Pharmaceuticals Korea Co., Ltd.
• Korea Genetic Pharmaceutical Co., Ltd.
• Jeil Pharmaceutical Co., Ltd.
• Ahn-gook Pharmaceutical Co., Ltd.
•  Kwang Dong Pharmaceutical Co., Ltd.

Korea :

• Korean University
• Pusan National university
• Catholic University of Daegu
• Chonnam National University
• Chosun University
• Chung-Ang University
• Chungbuk National University
• Chungnam National University
• Dongduk Women's University
• Duksung Women's University
• Ajou University

• Kyungpook National University
• Sookmyung Women's University
• Seoul National University
• Sungkyunkwan University
• Wonkwang University
• Woosuk University
• Yeungnam University
• Yonsei University

ConferenceSeries Ltd is organizing international conference “9^th Annual Congress on Drug Design & Drug Formulation  ” scheduled during October 19-20, 2017 Seoul, South Korea.

Drug Formulation is a process in Pharmaceutical sciences. Formulation means compounding of single or mixture of active ingredients, excipients like Fillers, Disintegrants, Lubricants, Glidants, and Binders etc., are packed in a single pack to form a Pharmaceutical Drug. Formulation deals with Active Pharmaceutical Ingredient in Packaging of finished product which means Analytical R & D, Formulation R & D, Blending, Drying, Punching or Filling, Packaging. Formulations are of different dosage forms like Oral Dosage Forms, Parenteral Dosage Forms & topical dosage Forms. Pharmaceutical drug formulation is the development of a bioavailable, stable and optimal dosage form for a precise administration route.

In the light theme, the conference series aims to provide a forum for international researchers from various research areas of biomedical, Pharmaceutical, clinical sciences by providing a platform for critical analysis of new data & also to share the latest cutting-edge research findings and results about all aspects of Drug Formulation.  

Conference Highlights:

• Drug Design and Development 
• Computer Aided Drug Design(CADD)
• Molecular Modeling in Drug Designing
• Biomarkers in Drug Design
• Drug Delivery and Distribution
• Pharmacology and Toxicology 
• Pre-Formulation & Formulation Aspects
• Traditional Medicine Design
• Types of Formulations
• Drug Formulation Procedures
• Pharmacokinetics and Pharmacodynamics
• Clinical Biotherapeutics
• Innovative Drug Discovery and Nanotechnology
• Novel Drug Delivery System
• Novel Drug Target Approaches
•  Medicinal Chemistry Drug Discovery advancenments
• Drug Product Manufacturing
• Chemical and Pharmaceutical Engineering
• Methodological Advancements in Pharmaceutical Industries
• Pharmaceutical regulatory affairs 
• Entrepreneur Investment

Market Analysis

Summary of 10^th Annual Congress on Drug Formulation & Analytical Techniques -2018:

Drug Formulation 2018 cordially invites you all to be a part of this conference which is mainly focusing on latest advancements emerging in the field of pharmaceutical sciences. ConferenceSeries Ltd is providing a great platform for thousands of pharmacists meet, learn, share and exchange views.

According to an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the market will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. Another research company, Business Monitor International, has made a forecast for the size and geographical composition of the global pharmaceutical market in 2020. However by 2020, the Asian pharmaceutical market has a share of 33% in global pharmaceutical market.

Pharmaceutical research work experienced tremendous growth in the past five years. In the next five years growth will increase to 40% as per the market value. Top Companies involved in the Pharmaceutical sales are Pfizer, Johnson & Johnson, Merck, Abbott, etc. from United States.

European countries also play major role in the sales of pharmaceutical products from companies like Novartis, GlaxoSmithKline, Astra Zeneca, French sanofi, Roche, etc.

There is rapid growth in the market and research environment in emerging economies such as Brazil, China and India, leading to a gradual migration of economic and research activities from Europe to these fast-growing markets. In 2012 the Brazilian and Chinese markets grew by 16% and 21% respectively compared to an average market growth of minus 2% for the five major European markets and minus 1% for the US market (source: IMS Retail Drug Monitor – February 2013).

In 2012 North America accounted for 41.0% of world pharmaceutical sales compared with 26.7% for Europe. According to IMS data, 62% of sales of new medicines launched during the period 2007-2011 were on the US market, compared with 18% on the European market.

In 2011 the pharmaceutical industry invested about € 29,200 million in R&D in Europe. A decade of strong US market dominance led to a shift of economic and research activity towards the US from 1995-2005. Additionally, Europe is now facing increasing competition from emerging economies: rapid growth in the market and research environments in countries such as Brazil and China are contributing to the move of economic and research activities to non-European markets. The geographical balance of the pharmaceutical market – and ultimately the R&D base – is likely to shift gradually towards emerging economies.

Importance & Scope:

Thanks to advances in science and technology, the research based pharmaceutical industry is entering an exciting new era in medicines development. According to an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the market will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. Another research company, Business Monitor International, has made a forecast for the size and geographical composition of the global pharmaceutical market in 2020. However by 2020, the Asian pharmaceutical market has a share of 33% in global pharmaceutical market.

Why Australia??

 

Australia's pharmaceutical market is set to ascend from simply over $22.85 billion in 2016 to $25.2 billion by 2020, as indicated by research and counseling firm Global Data. The reports highlight various open doors open to organizations planning to put resources into the Australian pharmaceutical industry, including expanding outside direct venture (FDI), the developing nonexclusive medications advertise, and a good duty condition. Other central point driving development in Australia's pharmaceuticals advertise incorporate the expanding elderly populace and its related malady trouble, alongside all around characterized administrative rules and the rising commonness of non-transmittable ailments because of an inexorably inactive lifestyle. Australia's human services market is set to develop to an amazing $42.5 billion by 2020, driven by all inclusive social insurance scope given by Medicare and great access to offices, for example, government-sponsored drugs, as indicated by research and counseling firm GlobalData. 

 

The 2015 PwC pharmaceutical industry study catches the aggregate perspectives of the Australian pharma segment and investigates the business' key difficulties, patterns and openings. As of late, the Australian pharma industry has been portrayed by a more aggressive market; noteworthy headways in innovation; obliged spending plans; real change; and expanding investigation from payers, controllers and the group. This has prompted pharmaceutical organizations reassessing their plans of action to guarantee they stay responsive.

 

Conference Highlights:

• Pharmaceutical Formulations
• Drug Formulation Procedures
• Pharmacology and Toxicology
• Analytical Methodology
• Advances in Chromatography and Mass Spectrometry
• Novel Approaches to Analytical and Bioanalytical Methods
• Applications of Analytical and Bio analytical Methods
• Bio analytical Methodology
• NMR and Analysis of Small Organic Molecules
• Analytical Techniques in Immuno Chemistry
• New Instrumentation and Equipment
• Analytical Chemistry and Engineering

Why to attend??

Drug Formulation 2018 conference will feature 12 technical sessions, a poster session, exhibit hall, keynote lectures and special features include workshop/symposium.

Drug Formulation 2018 is a perfect platform for scientists, decision-makers and students to come together, compare findings, and discuss the science of the future. Share your research with an engaged audience of your peers from around the globe; learn from scientific trail blazers who are designing more sustainable processes; find out how Pharmaceutical innovations are inspiring new businesses and product lines.

Target Audience:

Noble Laureates, Presidents, Vice-Presidents, Directors, Chairs, Co-Chairs, Department Heads, Non-PhD Students, PhD Students, etc. Vendors will have the opportunity to introduce the latest advancements in pharmaceutical sciences to a diverse audience by becoming a conference sponsor via exhibits and/or workshops.

• Industry       -  21%
• Student        -  17%
• Academia    -  42%
• Government - 11%
• Others           -  9%

Pharmacy Student Organizations:

• APV Students Server, ETH Zurich, Switzerland
• Aston Pharmacy Association, Aston University, Aston Triangle, Birmingham, UK
• British Pharmaceutical Students Association, London, UK
• European Pharmaceutical Students' Association, Leiden, The Netherlands
• Finnish Pharmaceutical Students' Association, Helsingin Yliopisto, Finland
• German Pharmacy Student Organisation Bundesverband der Pharmaziestudierenden in Deutschland
• Manchester University Pharmaceutical Society, Manchester, USA
• Pharma-World Forum, India
• PharmaLinks for Students, Eschborn, Germany
• Swedish National Association of Pharmacy Students (SNAPS), in Uppsala, Sweden
• University of Texas Acacdemy of Students of Pharmacy
• UT college of Pharmacy SNPhA chapter, Austin, TX 
• Virginia Academy of Students of Pharmacy

Pharma Associations in Globe:

• European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
• Drug Information Association (DIA)
• European Generic Medicines Association
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
• European Pharmaceutical Market Research Association (EphMRA)
• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
• Japan Pharmaceutical Manufacturers Association (JPMA)
• New York Health Products Council (NYHPC)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Irish Pharmaceutical Healthcare Association (IPHA)

Healthcare CRO Market to Reach $45.2 Billion By 2022

 

Worldwide Healthcare CRO industry is relied upon to achieve USD 45.2 billion by 2022, as indicated by another report by Grand View Research Inc. With the expanding number of licenses lapsing, expanding number of organizations to recognize biologics and new mixes and developing R&D costs, tranquilize creator and support organizations are under weight to supplant the income misfortune particularly because of generics, which has additionally made medication advancement more costly and complex. 

 

Pharmaceutical industry is encountering a fairly extreme redistribution of R&D exercises to new geographic locales. As per the Biopharma Cold Chain 2012 Sourcebook, in 2016 up to 65% of development in clinical research will originate from studies led in developing business sector areas: Asia Pacific, Eastern Europe and South America. While the greater part of clinical trials are started with the true objective of NDA endorsement in the US and in Western Europe, most by far of potential review subjects live outside of these areas. In this manner, there is an obviously identifiable need to grow top notch, financially savvy clinical trial framework capacities in Asia-Pacific locale, Latin America, Eastern Europe and possibly in North and South Africa. BRICS nations have shown eagerness to make their patients more accessible to worldwide clinical trials. For example, Russia and China have as of late made strides towards improving the dispatch of clinical trials.

We are uninformed of correct approved insights which precisely appraise the volume of clinical trial coordinations administrations. Along these lines, such volume is customarily figured as a rate of the aggregate clinical trials costs. As indicated by the gauge made by Evaluate Pharma, in the following 5 years the clinical trials market will demonstrate a steady low development of 2-2.5% every year, while being joined by a huge outlook change in the operational structure of icy chain coordinations and clinical trial supply, the expenses of which (counting fabricating), by different assessments, may reach up to 20% of the aggregate R&D costs. 

 

 

As per a similar report, this pattern of lopsided development will originate from an expansion in clinical trials of professionally prescribed solutions where calculated costs are customarily higher than those of trials of nonexclusive items. Additionally critical is the forecast that by 2020 R&D undertakings of main 20 pharmaceutical organizations will represent over 60% of aggregate clinical trial costs.

 

ConferenceSeries Ltd  genially invites all the participants across the sphere to attend our prestigious conference “9^th Annual Congress on Drug Design & Drug Formulation” scheduled during October 19-20, 2017 Seoul, South Korea. Drug Formulation 2017 is an outstanding event which brings together a unique and International mix of large & medium Pharmaceutical industries/companies, leading top universities, research institutions building the conference a perfect podium to share their experience, foster collaborations across industry and academia, to evaluate emerging technologies across the globe.

 Track 1: Drug Desig and Development 

Drug design is the method of inventing innovative medications. Drug design defines the design of molecules that are corresponding in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which repeatedly results in a medicinal benefit to the patient. Discovery of drugs is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether conversations occur. Basically, drug design involves design of small molecules that are harmonizing in shape and charge to the bio molecular target to which they act together and consequently will bind to it.

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to expect the conformation of the small molecule and to model conformational deviations in the biological target of drugs  that may occur when the small molecule binds to it. Molecular mechanics procedures may also be used to provide semi-quantitative prediction of the binding affinity. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by suitable experimental affinities to computationally derived interaction energies between the small molecule and the target.

Relevant Conferences:   

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 2:  Computer Aided Drug Design ( CADD )

The processes of designing a new drug by using bioinformatics implements have opened a new area of drug research and development. Computational techniques assist us in searching drug target and in designing drug. Bioinformatics affects a new drug design in the following drug design path.

By using computational methods and the 3D structural information of the protein target, we are now able to scrutinise the detailed underlying molecular and atomic interactions involved in ligand:protein interactions and thus interpret experimental results in detail. The use of computers in drug discovery bears the additional advantage of delivering new drug candidates more rapidly and cost-efficiently. Computer-aided drug discovery has recently had important successes: new ligands have been predicted along with their receptor-bound structures and in several circumstances the achieved hit rates (ligands discovered per molecules tested) have been significantly greater than through experimental high-throughput screening. Strategies for CADD vary depending on the extent of structural and other information available regarding the target (enzyme/receptor) and the ligands.

Computer-aided drug design (CADD) is an exciting and diverse discipline where various aspects of applied and basic  drug research merge and stimulate each other. In the early stage of a drug discovery process, researchers may be faced with little or no structure activity relationship (SAR) information. The process by which a new drug is brought to market stage is mentioned to by a number of names most commonly as the development chain or “pipeline” and comprises of a number of distinct stages. To drug design a rational drug, we must firstly find out which proteins can be the drug targets in pathogenesis. In present review we reported a brief history of CADD, DNA as target, receptor theory, structure optimization, structure-based drug design, virtual high-throughput screening (vHTS), graph machines. All the world’s major pharmaceutical and biotechnology companies use computational design tools.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 3: Molecular Modeling in Drug Designing

Molecular modeling has become a valuable and essential tool to medicinal chemists in the drug design process. Molecular modeling designates the generation, manipulation or representation of three-dimensional structures of molecules and associated physico-chemical properties. The aim of this review is to give an outline of studies in the field of medicinal chemistry in which molecular modeling has helped in the discovery process of new drugs. The emphasis will be on lead generation and optimization. It involves a range of computerized techniques based on theoretical chemistry methods and experimental data to expect molecular and biological properties. Structure-based drug discovery is central to the efficient development of therapeutic agents and to the understanding of metabolic processes.

The traditional way of drug discovery is the experimental screening of large collections of chemicals against a biological target (high-throughput screening or HTS) for identifying new lead compounds. The application of rational, structure-based drug design is proven to be more capable than the traditional way of drug discovery since it aims to understand the molecular basis of a disease and utilizes the knowledge of the three-dimensional (3D) structure of the biological target in the process. State of the art structure-based drug design methods include virtual screening and de novo drug design; these serve as an efficient, alternative approach to HTS.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 4: Biomarkers in Drug Design

Technological advancements in the molecular characterization of cancers have assisted researchers to identify an increasing number of key molecular drivers of cancer progression. These drug discoveries have led to multiple novel anticancer therapeutics, and clinical advantage in selected patient populations. Despite this, the identification of clinically relevant predictive biomarkers of response continues to lag behind. In this review, we discuss strategies for the molecular characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics. 

The discovery and evaluation of any novel biomarkers will ideally be specialised to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers, and are crucial to accelerating the drug development process.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

 Track 5 : Drug Delivery and Distribution

Drug Delivery is the process of governing a pharmaceutical compound to attain a therapeutic effect in humans or animals. For the cure of human diseases, nasal and pulmonary routes of drug delivery are ahead increasing importance. Drug release, absorption, distribution, and elimination profiles to improve product efficacy and safety, as well as patient convenience and compliance, can be modified through drug delivery technologies. Oral and parenteral are the most common routes of drug delivery, but alternative drug delivery is preferred in many situations.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH)

Track 6: Pharmacology and Toxicology

It is driven by chemistry but gradually directed by pharmacology and the clinical Sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and instruction is important in fulfilling the public health. The initiation of molecular biology and, in particular, of genomic sciences is having a deep conclusion on drug discovery. Emphasis is positioned on the contrast between the academic and industrial drug research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that drug research directors aspect are also emphasized. In  drug discovery process comprises the early phases of research, which are designed to identify an investigational drug and achieve primary tests in the lab. This first stage of the process proceeds almost three to six years. By the end, investigators hope to identify a accomplished drug aspirant to further study in the lab and in animal models, and then in people. These advances offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 7: Pre-Formulation & Formulation Aspects

Drug Formulation is the study of relationships between pre formulation, pharmaceutical formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its preferred form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was restricted only for assessing few characteristics, but today this process is being considered as a formulation strategy and hence tremendous technological advancement has been accomplished in this field which enables us to save time and money through planned management system and hence impacts Drug Formulation 2017 to be a formulation conference. Use of glorious statistical software even based on artificial neural networking are made the task of pre formulation and optimization process easier. Role of pre formulation studies techniques like freeze drying aspects projects the event Drug Formulation 2017 to pose as a freeze drying meeting in drug discovery, drug development plays major role in pharmaceutical formulation development and the revisions will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of formulations unique to each drug. NDDS conference will discuss on Premature Approaches, Present Scenario and Future Prospects of Pre formulation events. There are more than 1400 sustained or controlled release drugs have been approved all over the world. Pharmaceutical conferences discuss the state-of-art technology being applied and involve advances in formulation studies.

Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 8: Traditional Medicine Design

Traditional medicine is a combination of vast knowledge, skills and practices based on the theories, beliefs and experiences from inherent  to different cultures, whether explicable or not. But used in the maintenance of health as well as in the prevention, diagnosis, treatment of physical and mental illness. Traditional medicine comprises medical aspects of traditional knowledge that developed over generations within various societies before the era of modern medicine. Traditional Medicine modernization is the only way of TM development and also an in effect approach to the development of new drugs and the innovation of potential drug targets (PDTs). Discovery and validation of PTDs has become the “bottle-neck” restricted new drug research and development and is straightaway solved.

Relevant conference:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA.

Track 9: Types of Formulations

Drug Formulations are classified into two types: based on Route of administration and Physical form. Based on route of administration they are classified as Oral, Topica, Rectal, Parenteral, Vaginal, Inhaled, Ophthalmic and octic . A route of administration is the path by which a drug, fluid, poison, or other substance is involved into the body Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be categorised based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Relevant conference:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 10: Drug Formulation Procedures

The drug subjected to drug development undergo number of trials and are screened at different stages to produce a final potent drug for the treatment of various diseases. During this process different properties are checked to see whether the drug is non-toxic to living system and is therapeutic or not. Using suitable excipients and technological preparations the active substances are formulated into final dosage form. The final product is the Actual composition of preparation, manufacturing specification.

A detailed analysis of the industry structure of contract manufacturing, contract research and contract packaging has been conducted. Revenues are broken down by type of industry. Sales figures are estimated for the five-year period from 2013 through 2018. The United States is currently spending almost $250 billion a year for prescription drugs. If drugs were sold in a competitive market, without government-imposed patent monopolies, this might achieve savings up to $200 billion a year.     

Relevant conference:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 11: Pharmacokinetics and Pharmacodynamics

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.

Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of achievement is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall

Relevant conference:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 12: Clinical Trails & Biotherapeutics

Clinical Biotherapeutic aspects including study drug design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 13:   Innovative Drug Discovery and Nanotechnology

Size reduction is a fundamental unit operation having important applications in pharmacy. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better drug formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nano meter size range enhance performance in a variety of dosage forms. Major advantages of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.

Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative and highly specialized field, which will revolutionize the pharmaceutical industry in near future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against many diseases. It helps in detecting the antigen associated with diseases such as cancer, diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and viruses associated with infections. It is expected that in next 10 years market will be flooded with nanotechnology devised medicine

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 14: Novel Drug Delivery System

“Novel Drug delivery System (NDDS) refers to the formulations, systems and technologies for transporting a pharmaceutical compound in the body as it is needed to safely achieve its desired therapeutic effects. Drug delivery systems (DDS), are based on approaches that are interdisciplinary and that combine pharmaceutics, bio conjugate chemistry, and molecular biology. drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of provision is largely initiated on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is exclusively diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a susceptible drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted dispute system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more constant effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the drug dosages.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 15: Novel Drug Target Approaches

Identifying drug targets plays essential roles in designing new drugs and combating diseases. Unfortunately, our current understanding about drug targets is far from comprehensive. Screening drug targets in the lab is an expensive and time-consuming procedure. In the past decade, the accumulation of various types of study of science related data makes it possible to develop computational approaches to predict drug targets. Non-communicable diseases such as cancer, atherosclerosis and diabetes are responsible for most important social and health affliction as millions of people are dying every year. Out of which, atherosclerosis is the leading cause of deaths worldwide. The lipid abnormality is one of the most important modifiable risk factors for atherosclerosis. Both genetic and environmental components are associated with the development of atherosclerotic plaques. Immune and inflammatory mediators have a complex role in the initiation and progression of atherosclerosis. Understanding of all these processes will help to invent a range of new biomarkers and novel treatment modalities targeting various cellular events in acute and chronic inflammation that are accountable for atherosclerosis. Several biochemical pathways, recetors and nzymes are involved in the development of atherosclerosis that would be possible targets for improving strategies for disease diagnosis and management.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 16: Medicinal Chemistry and Drug Discover Advancements

Medicinal Chemistry is a branch of chemistry which especially agreements with synthetic organic chemistry and pharmacology including various other biological specialties which is involved with design, chemical creation and development of drug for marketing of pharmaceutical agents. It combines knowledge and capacities from the fields of cheminformatics, molecular modeling and important bioinformatics and demands an in-depth appreciative of the physico-chemical properties of a three-dimensional molecule. The information base required by today's medicinal chemist has increased dramatically and has highlighted an rising challenge for chemists to understand the growing field of drug design.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Track 17: Drug Product Manufacturing

Drug manufacturing (Pharmaceutical Manufacturing) is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be demolished down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others. The changing pharmaceutical landscape is a popular discussion point as of late. Armed with a fresh, non-blockbuster-reliant business model and treatment options that are expanding from small molecules to a range of new, more targeted therapies, the industry is at what PwC calls, “a critical juncture.”

Parenteral drug delivery is the second largest segment of this transformative pharmaceutical market covered only by the more mature oral solid dosage forms  accounting for nearly 30 percent of total pharma market share. According to Survey, the market for parenteral drug delivery  products is projected to rise over 10 percent annually to $86.5 billion in 2019.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 18: Chemical and Pharmaceutical Engineering

Pharmaceutical engineering is a branch of pharmaceutical science and technology that involves development and manufacturing of products, processes, and components in the pharmaceuticals industry (i.e. drugs & biologics). While developing pharmaceutical products involves many interrelated disciplines (e.g. medicinal chemists, analytical chemists, clinicians/pharmacologists, pharmacists, chemical engineers, biomedical engineers, etc.), the specific subfield of "pharmaceutical engineering" has only emerged recently as a divergent engineering discipline. This now brings the problem-solving principles and quantitative training of engineering to complement the other scientific fields already involved in drug development.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 19: Methodological Advancements in Pharmaceutical Industries

As drug developers and manufacturers of life-saving products, the world’s leading pharmaceutical companies play an important eccentric in improving access to medicine for the world’s poor. Through their own initiatives and in collaboration with other relevant stakeholders such as multi-lateral organizations, governments and the global health community, these companies are increasingly helping to address the admittance to medicine challenge. In order to suitably capture the industry’s progress in line with society’s evolving expectations, the Access to Medicine Index methodology is systematically reviewed every two years. While maintaining as much consistency as possible for the purpose of trend analysis, the methodology is adjusted where needed.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 20: Pharmaceutical Regulatory Affairs

Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. The pharmaceutical industry deals with an increasing number of interesting drug candidates, all of which necessitate the involvement of the Regulatory Affairs’ department. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment. But they also play an important operational role, for example, by considering the best processes to follow and enabling structured interaction with regulatory authorities. Regulatory Affairs is driven by good science and accordingly nothing remains static.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA

Track 21: Entrepreneur Investment

For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start or expand their business. If you’re thinking about a business opportunity that will require investment, then attend networking events in your area to identify key members of the investor community and meet other entrepreneurs. It is never too early to approach potential investors and it may be easier to create an informal relationship when you’re not actively seeking investment for your start-up.

Relevant Conferences:

2^nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3^rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4^th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16^th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11^thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9^th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14^th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11^th World Drug Delivery Summit October 16-18, 2017, New York, USA